Total Payments
$4,716
2024 Payments
$421.96
Companies
27
Transactions
159
Medicare Patients
1,846
Medicare Billing
$409,470
Payment Breakdown by Category
Food & Beverage$2,998 (63.6%)
Other$1,639 (34.7%)
Education$61.23 (1.3%)
Travel$18.00 (0.4%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $2,998 | 154 | 63.6% |
| Honoraria | $1,620 | 1 | 34.4% |
| Education | $61.23 | 2 | 1.3% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $18.54 | 1 | 0.4% |
| Travel and Lodging | $18.00 | 1 | 0.4% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Paratek Pharmaceuticals, Inc. | $1,872 | 7 | $0 (2024) |
| Allergan, Inc. | $510.19 | 36 | $0 (2020) |
| ABBVIE INC. | $389.99 | 20 | $0 (2024) |
| Astellas Pharma US Inc | $311.29 | 12 | $0 (2024) |
| Merck Sharp & Dohme LLC | $299.76 | 15 | $0 (2024) |
| ViiV Healthcare Company | $251.34 | 13 | $0 (2020) |
| Janssen Scientific Affairs, LLC | $201.37 | 6 | $0 (2019) |
| Gilead Sciences, Inc. | $110.87 | 6 | $0 (2024) |
| Shire North American Group Inc | $87.70 | 7 | $0 (2018) |
| Theravance Biopharma, Inc. | $83.91 | 5 | $0 (2018) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $421.96 | 16 | Merck Sharp & Dohme LLC ($111.55) |
| 2023 | $360.29 | 16 | Astellas Pharma US Inc ($167.26) |
| 2022 | $288.34 | 13 | ABBVIE INC. ($148.40) |
| 2021 | $288.10 | 16 | AbbVie Inc. ($141.88) |
| 2020 | $107.41 | 6 | ViiV Healthcare Company ($46.21) |
| 2019 | $1,960 | 17 | Paratek Pharmaceuticals, Inc. ($1,790) |
| 2018 | $431.96 | 31 | Allergan Inc. ($149.16) |
| 2017 | $857.48 | 44 | Allergan Inc. ($209.34) |
All Payment Transactions
159 individual payment records from CMS Open Payments — Page 1 of 7
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/12/2024 | Insmed, Inc. | Arikayce (Drug) | Food and Beverage | In-kind items and services | $33.86 | General |
| Category: Respiratory | ||||||
| 11/12/2024 | Melinta Therapeutics, LLC | Rezzayo (Drug), Kimyrsa, Vabomere | Food and Beverage | In-kind items and services | $25.28 | General |
| Category: ANTIFUNGALS | ||||||
| 10/17/2024 | Astellas Pharma US Inc | Cresemba (Drug) | Food and Beverage | In-kind items and services | $33.24 | General |
| Category: Infectious Diseases | ||||||
| 09/12/2024 | Astellas Pharma US Inc | Cresemba (Drug) | Food and Beverage | In-kind items and services | $34.49 | General |
| Category: Infectious Diseases | ||||||
| 09/04/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $30.94 | General |
| 07/17/2024 | Merck Sharp & Dohme LLC | — | Food and Beverage | In-kind items and services | $32.39 | General |
| 07/10/2024 | Melinta Therapeutics, LLC | Rezzayo (Drug), Kimyrsa, Orbactiv | Food and Beverage | In-kind items and services | $30.83 | General |
| Category: ANTIFUNGALS | ||||||
| 06/28/2024 | Merck Sharp & Dohme LLC | DIFICID (Drug), RECARBRIO, ZERBAXA | Food and Beverage | In-kind items and services | $20.33 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 05/15/2024 | Merck Sharp & Dohme LLC | — | Food and Beverage | In-kind items and services | $31.22 | General |
| 05/10/2024 | Paratek Pharmaceuticals, Inc. | NUZYRA (Drug) | Food and Beverage | In-kind items and services | $19.11 | General |
| Category: ANTIBIOTIC | ||||||
| 04/15/2024 | Paratek Pharmaceuticals, Inc. | NUZYRA (Drug) | Food and Beverage | In-kind items and services | $23.56 | General |
| Category: ANTIBIOTIC | ||||||
| 04/09/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug), XIFAXAN, TRULANCE | Food and Beverage | In-kind items and services | $15.78 | General |
| Category: Gastroenterology | ||||||
| 03/20/2024 | La Jolla Pharmaceutical Company | XERAVA (Drug) | Food and Beverage | In-kind items and services | $18.45 | General |
| Category: TETRACYCLINE CLASS ANTIBACTERIAL | ||||||
| 03/12/2024 | Astellas Pharma US Inc | Cresemba (Drug) | Food and Beverage | In-kind items and services | $30.28 | General |
| Category: Infectious Diseases | ||||||
| 02/29/2024 | ABBVIE INC. | TEFLARO (Drug), AVYCAZ, DALVANCE | Food and Beverage | In-kind items and services | $14.59 | General |
| Category: ANTI-INFECTIVE | ||||||
| 01/10/2024 | Merck Sharp & Dohme LLC | PIFELTRO (Drug), DELSTRIGO, DIFICID | Food and Beverage | In-kind items and services | $27.61 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 11/10/2023 | Cumberland Pharmaceuticals, Inc. | VIBATIV (Drug) | Education | In-kind items and services | $44.99 | General |
| Category: INFECTIONS AND INFECTIOUS DISEASES | ||||||
| 10/13/2023 | Astellas Pharma US Inc | Cresemba (Drug) | Food and Beverage | In-kind items and services | $32.59 | General |
| Category: Infectious Diseases | ||||||
| 10/02/2023 | Paratek Pharmaceuticals, Inc. | NUZYRA (Drug) | Food and Beverage | In-kind items and services | $19.02 | General |
| Category: ANTIBIOTIC | ||||||
| 09/19/2023 | AbbVie Inc. | AVYCAZ (Drug) | Food and Beverage | In-kind items and services | $21.29 | General |
| Category: ANTI-INFECTIVE | ||||||
| 08/29/2023 | Astellas Pharma US Inc | Cresemba (Drug) | Food and Beverage | In-kind items and services | $16.77 | General |
| Category: Infectious Diseases | ||||||
| 06/16/2023 | Merck Sharp & Dohme LLC | DIFICID (Drug), RECARBRIO, ZERBAXA | Food and Beverage | In-kind items and services | $23.70 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 06/07/2023 | Astellas Pharma US Inc | Cresemba (Drug) | Food and Beverage | In-kind items and services | $24.25 | General |
| Category: Infectious Diseases | ||||||
| 05/25/2023 | Hydrofera LLC | HYDROFERA BLUE (Device) | Food and Beverage | In-kind items and services | $12.91 | General |
| Category: WOUND CARE | ||||||
| 04/26/2023 | AbbVie Inc. | DALVANCE (Drug) | Food and Beverage | In-kind items and services | $17.12 | General |
| Category: ANTI-INFECTIVE | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 8 | 307 | 543 | $154,880 | $44,633 |
| 2022 | 13 | 477 | 5,620 | $409,413 | $133,792 |
| 2021 | 11 | 532 | 6,518 | $402,977 | $145,243 |
| 2020 | 8 | 530 | 992 | $203,506 | $85,802 |
Total Patients
1,846
Total Services
13,673
Medicare Billing
$409,470
Procedure Codes
40
All Medicare Procedures & Services
40 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 82 | 197 | $49,250 | $12,145 | 24.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 40 | 92 | $23,000 | $8,967 | 39.0% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 70 | 79 | $31,600 | $7,458 | 23.6% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 37 | 72 | $23,400 | $6,783 | 29.0% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 24 | 24 | $12,000 | $3,321 | 27.7% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 24 | 41 | $7,380 | $2,845 | 38.6% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 14 | 17 | $5,100 | $2,281 | 44.7% |
| 99231 | Subsequent hospital care with straightforward or low level of medical decision making, per day, if using time, at least 25 minutes | Facility | 2023 | 16 | 21 | $3,150 | $833.07 | 26.4% |
| J0875 | Injection, dalbavancin, 5 mg | Office | 2022 | 15 | 4,725 | $186,638 | $52,994 | 28.4% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 77 | 237 | $50,185 | $19,434 | 38.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 64 | 183 | $45,750 | $18,418 | 40.3% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 68 | 72 | $29,070 | $11,268 | 38.8% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 75 | 159 | $24,381 | $9,052 | 37.1% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 51 | 56 | $15,920 | $5,841 | 36.7% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 18 | 26 | $7,800 | $3,813 | 48.9% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 37 | 51 | $9,180 | $3,683 | 40.1% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 15 | 15 | $6,375 | $2,579 | 40.5% |
| 99183 | Management of oxygen chamber therapy | Facility | 2022 | 12 | 30 | $19,500 | $2,564 | 13.1% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2022 | 19 | 38 | $8,550 | $1,954 | 22.9% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 14 | 14 | $4,900 | $1,758 | 35.9% |
| 99231 | Follow-up hospital inpatient care per day, typically 15 minutes | Facility | 2022 | 12 | 14 | $1,164 | $433.57 | 37.2% |
| J0875 | Injection, dalbavancin, 5 mg | Office | 2021 | 17 | 5,625 | $222,188 | $70,739 | 31.8% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 101 | 211 | $42,833 | $17,356 | 40.5% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 65 | 161 | $35,306 | $15,739 | 44.6% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 94 | 183 | $25,803 | $10,535 | 40.8% |
About Dr. Ronald Devine, MD
Dr. Ronald Devine, MD is a Infectious Disease healthcare provider based in Atlanta, Georgia. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/19/2006. The National Provider Identifier (NPI) number assigned to this provider is 1174637532.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Ronald Devine, MD has received a total of $4,716 in payments from pharmaceutical and medical device companies, with $421.96 received in 2024. These payments were reported across 159 transactions from 27 companies. The most common payment nature is "Food and Beverage" ($2,998).
As a Medicare-enrolled provider, Devine has provided services to 1,846 Medicare beneficiaries, totaling 13,673 services with total Medicare billing of $409,470. Data is available for 4 years (2020–2023), covering 40 distinct procedure/service records.
Ad
Practice Information
- Specialty Infectious Disease
- Location Atlanta, GA
- Active Since 08/19/2006
- Last Updated 03/07/2023
- Taxonomy Code 207RI0200X
- Entity Type Individual
- NPI Number 1174637532
Products in Payments
- NUZYRA (Drug) $1,872
- AVYCAZ (Drug) $539.19
- Cresemba (Drug) $287.92
- DALVANCE (Drug) $259.13
- PREZCOBIX (Drug) $162.69
- VIBATIV (Drug) $142.64
- TIVICAY (Drug) $113.18
- CUVITRU (Biological) $87.70
- Symtuza (Drug) $83.83
- XERAVA (Drug) $78.66
- ISENTRESS (Drug) $73.79
- TRIUMEQ (Drug) $70.46
- DIFICID (Drug) $66.89
- Mytesi (Drug) $57.77
- Rezzayo (Drug) $56.11
- TEFLARO (Drug) $55.15
- PIFELTRO (Drug) $50.27
- Arikayce (Drug) $50.10
- DOVATO (Drug) $46.21
- Heplisav-B (Drug) $32.67
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Infectious Disease Doctors in Atlanta
Dr. Larry Anderson, M.d, M.D
Infectious Disease — Payments: $300,125
Infectious Disease $300,125
Quintin Robinson, Md, MD
Infectious Disease — Payments: $263,508
Infectious Disease $263,508
Mr. James Mcmillen, Md, MD
Infectious Disease — Payments: $191,625
Infectious Disease $191,625
Dr. Bernard Branson, Md, MD
Infectious Disease — Payments: $102,962
Infectious Disease $102,962
Dr. Walter Orenstein, Md, MD
Infectious Disease — Payments: $80,951
Infectious Disease $80,951
Kimberly Workowski, M.d, M.D
Infectious Disease — Payments: $71,380
Infectious Disease $71,380